3 active not recruiting, 3 completed, 2 unknown, 1 recruiting. 9 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Active not recruiting 3, Completed 3, Unknown 2, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Primary Peritoneal Serous Adenocarcinoma: new trials by email Literature Review of Primary Peritoneal Serous Adenocarcinoma trials Research Report on Primary Peritoneal Serous Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial Chemotherapy, Laparotomy, Minimally Invasive Surgery - Advanced Ovarian Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Recruiting | M.D. Anderson Cancer Center | 580 | 2020-08-05 | 2026-09-14 |
| Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer Cediranib, Cediranib Maleate, Computed Tomography - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 582 | 2016-05-03 | 2026-10-01 |
| Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride - Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 260 | 2014-04-11 | 2026-08-04 |
| Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Behavioral Dietary Intervention, Compliance Monitoring, Counseling - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Unknown | Gynecologic Oncology Group | 1070 | 2012-06-18 | 2018-02-19 |
| Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Computed Tomography - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 692 | 2010-09-27 | 2026-05-29 |
| Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1560 | 2009-08-11 | 2026-06-02 |
| Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Docetaxel - Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1052 | 2007-12-06 | 2025-12-30 |
| Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1873 | 2005-09-01 | 2019-07-23 |
| Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Clinical Observation, Laboratory Biomarker Analysis, Paclitaxel - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Unknown | GOG Foundation | 1157 | 2005-03-21 | 2021-09-30 |
Fallopian Tube Neoplasms (7) · Brenner Tumor (6) · Ovarian Neoplasms (4) · Adenocarcinoma, Clear Cell (1) · Adenocarcinoma, Mucinous (1) · Carcinoma (1) · Cystadenocarcinoma, Serous (1)
Neoplasms (9) · Adnexal Diseases (8) · Endocrine System Diseases (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Genital Diseases (8) · Genital Diseases, Female (8) · Genital Neoplasms, Female (8) · Gonadal Disorders (8) · Ovarian Diseases (8) · Urogenital Diseases (8) · Urogenital Neoplasms (8) · Fallopian Tube Diseases (7) · Neoplasms by Histologic Type (7) · Neoplasms by Site (7)
Paclitaxel (7) · Taxes (7) · Bevacizumab (4) · Carboplatin (4) · Disulfides (4) · Immunoglobulin G (4) · Doxorubicin (2) · Topotecan (2) · liposomal doxorubicin (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Cisplatin (1) · Counseling (1) · Docetaxel (1) · Drug Therapy (1) · Early Intervention, Educational (1)
National Cancer Institute (NCI) (6) · GOG Foundation (1) · Gynecologic Oncology Group (1) · M.D. Anderson Cancer Center (1)
United States (9) · Canada (4) · South Korea (4) · Japan (3) · Italy (1) · Mexico (1) · Netherlands (1) · Puerto Rico (1) · United Kingdom (1)
David Alberts (1) · David M Gershenson (1) · Joan L Walker (1) · John K Chan (1) · Jose A Rauh-Hain (1) · Jung-min Lee (1) · Larry J Copeland (1) · Robert Burger (1) · Robert L Coleman (1)
PMID 37185961, PMID 21941283, PMID 22204724, PMID 23219660, PMID 26487588, PMID 26933849, PMID 27394382, PMID 28438473, PMID 29550184, PMID 31002578, PMID 31216226, PMID 31722153, PMID 35123694, PMID 35144591, PMID 35759733, PMID 36252167, PMID 36608382, PMID 39361946, PMID 39570589
U10CA180868 (7), U10CA027469 (5), P50CA083639 (1), U10CA101165 (1), U10CA180830 (1), UG1CA189867 (1)